{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-093531","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.310166+00:00","generated_at":"2026-05-30T06:59:22.994039+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio Q3 net loss $12.1M; Phase 2 Alzheimer's trial fully enrolled; top-line data Q2 2025","bullets":["Net loss $12.1M vs $8.6M Q3 2023; R&D expenses $10.1M (up from $6.0M).","Cash and equivalents $33.6M as of Sept 30; raised $13.0M in securities purchase agreement.","Phase 2 AD trial (XPro) fully enrolled with 201 planned patients; top-line data expected Q2 2025.","INKmune in prostate cancer trial showed safety and NK cell activity in first cohort; highest dose cohort dosing began.","Received $2.5M R&D rebate from Australia in July."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-093531","json":"https://secwatch.observer/filing/0001213900-24-093531.json","markdown":"https://secwatch.observer/filing/0001213900-24-093531.md","text":"https://secwatch.observer/filing/0001213900-24-093531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024093531/0001213900-24-093531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024093531/ea0219289-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:59:22.994039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}